1Pinkel D. The use of body surface area as a criterion of drug dosage in cancerchemotherapy[J]. CancerRes, 1958,18:853- 856.
2Kaestncr S A,Sewelly GJ. Chemotherapy Dosing Part I: Scientific Basis for Current Practicc and Use of Body Suriacc Area [J]. Clinical Ontology,2007,19:23 -37.
3Freireich E J, Gehan E A, Rall D P,etal. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man[J]. Cancer Chemother Rep 1966,50:219- 244.
4Gurney H. How to calculate the dose of chemotherapy[J]. British Journal of Cancer, 2002,86 : 1297- 1302.
5Budrnan D R. Dose and dose intensity as determinants of outcome in the adiuvant treatment of breast cancer. The Cancer and Leukemia Group B[J]. J Natl Cancer Inst, 1998, 90 : 1205-1211.
6Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the random- ized trials[J]. Lancet,1998,352:930- 934.
8Newell D R. Getting the right dose in cancer chemotherapy- time to stop using surface area[J]. British Journal of Cancer, 2002,86:1207- 1208.
9Du Bois D, Du Bois E F. A formula to estimate the approximate surf'ace area if height and weight Be known[J]. Arch In tern Med, 1916, 17:863-871.
10Dana G Allen. Handbook of Veterinary Drugs[M]. Philadelphia: Lippincatt Willians & Wilkins, 2003 : 2 -3.
二级参考文献18
1Masson E,Zamboni WC.Pharmacokinetic optimisation of cancer chemotherapy:effects on outcomes [J]. Clin Pharmaco-kinet,1997,32:324-343.
2Reilly JJ,Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area:is it worthwhile? A review of theoretical and practical considerations [J]. Cancer Chemother Pharmacol,1993,32:411-418.
3Gurney H. Dose calculation of anticancer drugs:a review of the current practice and introduction of an alternative [J]. J Clin Oncol,1996,14:2590-2611.
4Koren G,Beatty K,Seto A,et al. The effects of impaired liver function on the elimination of antineoplastic agents [J]. Ann Pharmacother,1992,26:363-271.
5Donelli MG,Zucchetti M,Munzone E,et al. Pharmacokinetics of anticancer agents in patients with impaired liver function [J]. Eur J Cancer,1998,34:33-46.
6Joel SP,Shah R,Clark PI,et al. Predicting etoposide toxicity: relationship to organ function and protein binding [J]. J Clin Oncol,1996,14:257-267.
7Kintzel PE,Dorr RT. Anticancer drug renal toxicity and elimination:dosing guidelines for altered renal function [J]. Cancer Treat Rev,1995,21:33-64.
8Nguyen L,Chatelut E,Chevreau C,et al. Population pharmacokinetics of total and unbound etoposide[J].Cancer Chemother Pharmacol,1998,41:125-132.
9Arbuck SG, Douglass HO, Crom WR,et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function [J]. J Clin Oncol,1986,4:1690-1695.
10Canal P,Chatelut E,Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy [J]. Drugs,1998,56(6):1019-1038.
